Refractory Primary Central Nervous System Neoplasm: Clinical Trials

10 trials for Refractory Primary Central Nervous System Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 active not recruiting, 4 completed, 1 recruiting. 10 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 210Active not recruiting 5, Completed 4, Recruiting 1
Phase 11Recruiting 1

Follow Refractory Primary Central Nervous System Neoplasm: new trials by email Literature Review of Refractory Primary Central Nervous System Neoplasm trials Research Report on Refractory Primary Central Nervous System Neoplasm

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma
Phase 1 / Phase 2RecruitingNationwide Children's Hospital652022-11-212026-11-16
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Phase 2Active not recruitingNational Cancer Institute (NCI)202018-06-052026-11-13
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm
Phase 2Active not recruitingNational Cancer Institute (NCI)132018-04-172026-11-13
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)182017-11-282026-04-21
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)42017-11-082025-01-27
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)212017-10-302025-02-05
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)62017-09-142024-12-11
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma
Phase 2Active not recruitingNational Cancer Institute (NCI)92017-08-232026-11-13
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Phase 2Active not recruitingNational Cancer Institute (NCI)13772017-07-312026-11-13
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Phase 2Active not recruitingNational Cancer Institute (NCI)1092017-05-182026-11-13

Narrower conditions

Central Nervous System Neoplasms (10)  ·  Ependymoma (8)  ·  Glioma (8)  ·  Hepatoblastoma (8)  ·  Lymphoma, Non-Hodgkin (8)  ·  Neuroblastoma (8)  ·  Wilms Tumor (8)  ·  Histiocytosis, Langerhans-Cell (7)  ·  Medulloblastoma (7)  ·  Neuroectodermal Tumors, Primitive, Peripheral (7)  ·  Osteosarcoma (7)  ·  Rhabdoid Tumor (7)  ·  Rhabdomyosarcoma (7)  ·  Sarcoma (7)  ·  Sarcoma, Ewing (4)

Broader conditions

Neoplasms (10)  ·  Neoplasms by Histologic Type (10)  ·  Neoplasms by Site (10)  ·  Neoplasms, Glandular and Epithelial (10)  ·  Neoplasms, Nerve Tissue (10)  ·  Nervous System Diseases (10)  ·  Nervous System Neoplasms (10)  ·  Neuroectodermal Tumors (10)  ·  Neoplasms, Germ Cell and Embryonal (9)  ·  Neoplasms, Neuroepithelial (9)  ·  Neuroectodermal Tumors, Primitive (9)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)  ·  Female Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (8)  ·  Genetic Diseases, Inborn (8)

Interventions

Magnetic Resonance Spectroscopy (5)  ·  Phantoms, Imaging (5)  ·  Specimen Handling (5)  ·  X-Rays (5)  ·  Biopsy (4)  ·  Nuclear Medicine Department, Hospital (4)  ·  LY3023414 (2)  ·  Vemurafenib (2)  ·  ensartinib (2)  ·  erdafitinib (2)  ·  larotrectinib (2)  ·  olaparib (2)  ·  AZD 6244 (1)  ·  cabozantinib (1)  ·  ivosidenib (1)

Sponsors

National Cancer Institute (NCI) (9)  ·  Nationwide Children's Hospital (1)

Countries

United States (10)  ·  Puerto Rico (8)  ·  Australia (2)  ·  Canada (2)

Top investigators

AeRang Kim (1)  ·  Alice Lee (1)  ·  Carl E Allen (1)  ·  Donald W Parsons (1)  ·  Julia Glade-Bender (1)  ·  Katherine A Janeway (1)  ·  Margot Lazow, MD (1)  ·  Meredith S Irwin (1)  ·  Srivandana Akshintala (1)  ·  Theodore W Laetsch (1)

Results publications

PMID 31401903, PMID 33591402, PMID 34486544, PMID 35353553, PMID 35363510, PMID 38815151, PMID 38873934, PMID 41166674, PMID 42686334

NIH funding

U10CA180886 (9), UM1CA081457 (1)